Advertisement
Research ArticleArticle

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease

James John Beaudoin, Jacqueline Bezencon, Yanguang Cao, Katsuhiko Mizuno, Sharin E Roth, William J Brock and Kim L.R. Brouwer
Drug Metabolism and Disposition November 30, 2018, dmd.118.083907; DOI: https://doi.org/10.1124/dmd.118.083907

Data Supplement

  • Supplemental Data -

    Supplemental Table 1 - Individual wild-type (WT) and polycystic kidney (PCK) rat outflow perfusate appearance and biliary excretion rates

    Supplemental Table 2 - Body and liver weights of wild-type (WT) and polycystic kidney (PCK) rats

    Supplemental Figure 1 - Observed (DV) vs. predicted (IPRED) plots of outflow perfusate appearance and biliary excretion rates of tolvaptan (TVP) and DM-4103+DM-4107 in wild-type (A) and polycystic kidney (B) rats.

  View article